Table 1 Baseline patient characteristics
Previously untreated patients (N = 22)Previously treated patients (N = 18)All patients (N = 40)
Gender, n (%)
    Male13 (59%)10 (56%)23 (57%)
    Female9 (41%)8 (44%)17 (43%)
Age at inclusion (years); median (range)48.4 (31–74)52.2 (27–66)50.2 (27–74)
Age at first symptoms (years); median (range)43.6 (25.0–68.8)39.6 (25.0–65.8)41.6 (25.0–68.8)
Interval between diagnosis and treatment (months); median (range)1.8 (−0.5–64)10.9 (1.0–53.3)2.9 (−0.5–64)
Motor weakness
    Upper extremities22 (100%)17 (94%)39 (98%)
    Lower extremities5 (23%)10 (56%)15 (38%)
    Asymmetrical22 (100%)18 (100%)40 (100%)
    Distal20 (91%)18 (100%)38 (95%)
    No sensory impairment22 (100%)18 (100%)40 (100%)
    Amyotrophy17 (81%)14 (78%)31 (79%)
Anti-GM1 antibodies (IgM)
    Present10 (56%)11 (73%)21 (64%)
    Absent8 (44%)4 (27%)12 (36%)